Skip to content
Aton

Aton

  • EN
  • FR
  • EN
  • FR
  • Home
  • About Us
  • Our Strategy
  • Our Platforms
    • Our Platforms
    • Preclinical & Clinical Services
    • Monoclonal Antibodies Production
    • Laboratory Equipment Production
    • Human Tissue Provision
  • Insights & News
  • Contact Us
  • Investors
Newsletter Signup

"*" indicates required fields

Consent*

Terms and conditions of the bond issue with Vatel Capital

Post navigation

Previous post

Stemcis expands its international horizons with the opening of a subsidiary in the United States

Next post

Aton strengthens its financial resources by issuing a €1.5m convertible bond with Vatel Capital

Aton_footer_logo
ATON
  • Home
  • About Us
  • Our Strategy
  • Our Platforms
  • Insights & News
  • Contact Us
Investors
  • Investors
  • Documents
Sign up to our newsletter

"*" indicates required fields

Consent*
  • Cookies Policy
  • Privacy Policy
© ATON 2023